ROME, ITALY — Using the factor Xa inhibitor edoxaban (Savaysa/Lixiana, Daiichi Sankyo) to anticoagulate patients about to undergo electrical cardioversion for their atrial fibrillation (AF) seems ...
PHILADELPHIA, PA—For patients with obesity who are undergoing electrical cardioversion for atrial fibrillation (AF), delivering twice the energy with a simultaneous dual approach is a better option ...